Potential role of IFNα in adult lupus

Arthritis Research and Therapy

Volumn 12, Issue SUPPL. 1, 2010, Pages

  Rönnblom, Lars ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; FC RECEPTOR IIA; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 10; MONOCLONAL ANTIBODY; RECOMBINANT ALPHA INTERFERON; STAT4 PROTEIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; ANTINUCLEAR ANTIBODY; FC RECEPTOR; INTERFERON REGULATORY FACTOR; IRF5 PROTEIN, HUMAN; STAT4 PROTEIN, HUMAN; TLR7 PROTEIN, HUMAN; TLR9 PROTEIN, HUMAN;

ADULT; ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CLINICAL PRACTICE; ENDOSOME; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; IMMUNE SYSTEM; INTERFERON PRODUCTION; LUPUS VULGARIS; MONOCYTE; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VIRUS INFECTION; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; BLOOD; CEREBROSPINAL FLUID; DENDRITIC CELL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS NEPHRITIS; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; RISK; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANIMALS; ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; AUTOIMMUNITY; BIOLOGICAL MARKERS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ENDOSOMES; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MICE; MODELS, IMMUNOLOGICAL; MOLECULAR TARGETED THERAPY; RECEPTORS, IGG; RISK; STAT4 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9;

EID: 78549265981     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2884     Document Type: Review

References (87)

1. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979, 301:5-8. 10.1056/NEJM197907053010102, 449915.
2. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982, 25:401-406. 10.1002/art.1780250407, 6176248.
3. Preble OT, Rothko K, Klippel JH, Friedman RM, Johnston MI. Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med 1983, 157:2140-2146. 2187063, 6189954, 10.1084/jem.157.6.2140.
4. von Wussow P, Jakschies D, Hochkeppel H, Horisberger M, Hartung K, Deicher H. MX homologous protein in mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1989, 32:914-918.
5. Bengtsson A, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, Rönnblom L. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not antiretroviral antibodies. Lupus 2000, 9:664-671. 10.1191/096120300674499064, 11199920.
6. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006, 54:1906-1916. 10.1002/art.21890, 16736505.
7. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723. 2193846, 12642603, 10.1084/jem.20021553.
8. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100:2610-2615. 151388, 12604793, 10.1073/pnas.0337679100.
9. Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 2003, 5:279-287. 333417, 14680503, 10.1186/ar1015.
10. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003, 4:177-186. 10.1038/sj.gene.6363966, 12700592.
11. Peterson KS, Huang JF, Zhu J, D'Agati V, Liu X, Miller N, Erlander MG, Jackson MR, Winchester RJ. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 2004, 113:1722-1733. 420500, 15199407.
12. Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev 2008, 19:3-19. 2277216, 18248767, 10.1016/j.cytogfr.2007.10.006.
13. Cederblad B, Blomberg S, Vallin H, Perers A, Alm GV, Rönnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-α-producing cells. J Autoimmun 1998, 11:465-470. 10.1006/jaut.1998.0215, 9802930.
14. Blomberg S, Eloranta M-L, Magnusson M, Alm GV, Rönnblom L. Expression of the markers BDCA-2 and -4 and production of interferon-α by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum 2003, 48:2524-2532. 10.1002/art.11225, 13130472.
15. Robak E, Sysa-Jedrzejowska A, Robak T, Smolewski P. Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus: correlation with immunological status and disease-related symptoms. Clin Rheumatol 2006, 25:225-233. 10.1007/s10067-005-1163-0, 16432661.
16. Blomberg S, Eloranta M-L, Cederblad B, Nordlind K, Alm GV, Rönnblom L. Presence of cutaneous interferon-a producing cells in patients with systemic lupus erythematosus. Lupus 2001, 10:484-490. 10.1191/096120301678416042, 11480846.
17. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001, 159:237-243. 1850412, 11438470.
18. Rönnblom L, Alm GV. The natural interferon-α producing cells in systemic lupus erythematosus. Hum Immunol 2002, 63:1181-1193. 10.1016/S0198-8859(02)00757-7, 12480262.
19. Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum 2008, 58:251-262. 10.1002/art.23186, 18163476.
20. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008, 8:594-606. 10.1038/nri2358, 18641647.
21. Cao W, Manicassamy S, Tang H, Kasturi SP, Pirani A, Murthy N, Pulendran B. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol 2008, 9:1157-1164. 10.1038/ni.1645, 18758466.
22. Vallin H, Blomberg S, Alm GV, Cederblad B, Rönnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999, 115:196-202. 1905199, 9933442, 10.1046/j.1365-2249.1999.00772.x.
23. Vallin H, Perers A, Alm GV, Rönnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. J Immunol 1999, 163:6306-6313.
24. Båve U, Magnusson M, Eloranta M-L, Perers A, Alm GV, Rönnblom L. FcgRIIa is expressed on natural IFN-α producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J Immunol 2003, 171:3296-3302.
25. Rönnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006, 54:408-420. 10.1002/art.21571, 16447217.
26. Lövgren T, Eloranta ML, Båve U, Alm GV, Rönnblom L. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004, 50:1861-1872. 10.1002/art.20254, 15188363.
27. Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, Vlag J. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008, 17:371-375. 10.1177/0961203308089990, 18490410.
28. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007, 8:487-496. 10.1038/ni1457, 17417641.
29. Lood C, Gullstrand B, Truedsson L, Olin AI, Alm GV, Rönnblom L, Sturfelt G, Eloranta ML, Bengtsson AA. C1q inhibits immune complex-induced IFNα production in plasmacytoid dendritic cells. A novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum 2009, 60:3081-3091. 10.1002/art.24852, 19790049.
30. Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A, Akira S, Kelly KM, Reeves WH, Bauer S, Krieg AM. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005, 202:1575-1585. 2213330, 16330816, 10.1084/jem.20051696.
31. Lövgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Rönnblom L. Induction of interferon-α by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. Arthritis Rheum 2006, 54:1917-1927. 10.1002/art.21893, 16729300.
32. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533. 10.1056/NEJMoa021933, 14561795.
33. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005, 11:85-89. 10.1038/nm1167, 15619631.
34. Rönnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001, 22:427-431. 10.1016/S1471-4906(01)01955-X, 11473831.
35. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007, 8:492-502. 2702174, 17581626, 10.1038/sj.gene.6364408.
36. Izaguirre A, Barnes BJ, Amrute S, Yeow WS, Megjugorac N, Dai J, Feng D, Chung E, Pitha PM, Fitzgerald-Bocarsly P. Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J Leukoc Biol 2003, 74:1125-1138. 10.1189/jlb.0603255, 12960254.
37. Sigurdsson S, Nordmark G, Göring HH, Lindroos K, Wiman AC, Sturfelt G, Jönsen A, Rantapää-Dahlqvist S, Möller B, Kere J, Koskenmies S, Widen E, Eloranta ML, Julkunen H, Kristjansdottir H, Steinsson K, Alm G, Rönnblom L, Syvänen AC. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005, 76:528-537. 1196404, 15657875, 10.1086/428480.
38. Sigurdsson S, Goring HH, Kristjansdottir G, Milani L, Nordmark G, Sandling J, Eloranta ML, Feng D, Sangster-Guity N, Gunnarsson I, Svenungsson E, Sturfelt G, Jonsen A, Truedsson L, Barnes BJ, Alm G, Rönnblom L, Syvanen AC. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 2008, 17:872-881. 10.1093/hmg/ddm359, 18063667.
39. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. Association of the IRF5 risk haplotype with high serum interferon-α activity in systemic lupus erythematosus patients. Arthritis Rheum 2008, 58:2481-2487. 2621107, 18668568, 10.1002/art.23613.
40. Jacob CO, Zhu J, Armstrong DL, Yan M, Han J, Zhou XJ, Thomas JA, Reiff A, Myones BL, Ojwang JO, Kaufman KM, Klein-Gitelman M, McCurdy D, Wagner-Weiner L, Silverman E, Ziegler J, Kelly JA, Merrill JT, Harley JB, Ramsey-Goldman R, Vila LM, Bae SC, Vyse TJ, Gilkeson GS, Gaffney PM, Moser KL, Langefeld CD, Zidovetzki R, Mohan C. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA 2009, 106:6256-6261. 2669395, 19329491, 10.1073/pnas.0901181106.
41. Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, Ortmann W, Shifrin N, Petri MA, Kamboh MI, Manzi S, Seldin MF, Gregersen PK, Behrens TW, Ma A, Kwok PY, Criswell LA. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008, 40:1062-1064. 10.1038/ng.202, 19165919.
42. Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, Leon JM, Burtt NP, Guiducci C, Parkin M, Gates C, Plenge RM, Behrens TW, Wither JE, Rioux JD, Fortin PR, Graham DC, Wong AK, Vyse TJ, Daly MJ, Altshuler D, Moser KL, Gaffney PM. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 2008, 40:1059-1061. 2772171, 19165918, 10.1038/ng.200.
43. Tyler DR, Persky ME, Matthews LA, Chan S, Farrar JD. Pre-assembly of STAT4 with the human IFN-α/β receptor-2 subunit is mediated by the STAT4 N-domain. Mol Immunol 2007, 44:1864-1872. 2700023, 17095088, 10.1016/j.molimm.2006.10.006.
44. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, de Bakker PI, Le JM, Lee HS, Batliwalla F, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Klareskog L, Chen WV, Amos CI, Criswell LA, Seldin MF, Kastner DL, Gregersen PK. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007, 357:977-986. 2630215, 17804842, 10.1056/NEJMoa073003.
45. Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-α in lupus patients in vivo. J Immunol 2009, 182:34-38. 2716754, 19109131.
46. Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, Chung SA, Nititham J, Hom G, Kao AH, Demirci FY, Kamboh MI, Petri M, Manzi S, Kastner DL, Seldin MF, Gregersen PK, Behrens TW, Criswell LA. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet 2008, 4:e1000084. 2377340, 18516230, 10.1371/journal.pgen.1000084.
47. Sigurdsson S, Nordmark G, Garnier S, Grundberg E, Kwan T, Nilsson O, Eloranta ML, Gunnarsson I, Svenungsson E, Sturfelt G, Bengtsson AA, Jonsen A, Truedsson L, Rantapaa-Dahlqvist S, Eriksson C, Alm G, Goring HH, Pastinen T, Syvanen AC, Rönnblom L. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet 2008, 17:2868-2876. 2525501, 18579578, 10.1093/hmg/ddn184.
48. Cunninghame Graham DS, Akil M, Vyse TJ. Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families. Rheumatology (Oxford) 2007, 46:927-930. 10.1093/rheumatology/kel449, 17384181.
49. Moser KL, Kelly JA, Lessard CJ, Harley JB. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009, 10:373-379. 10.1038/gene.2009.39, 19440199.
50. Rönnblom LE, Alm GV, Öberg KE. Possible induction of systemic lupus erythematosus by interferon-a treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990, 227:207-210. 10.1111/j.1365-2796.1990.tb00144.x, 1690258.
51. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000, 43:1431-1442. 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E, 10902743.
52. Rönnblom LE, Alm GV, Öberg KE. Autoimmunity after α-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991, 115:178-183.
53. Strandberg L, Ambrosi A, Espinosa A, Ottosson L, Eloranta ML, Zhou W, Elfving A, Greenfield E, Kuchroo VK, Wahren-Herlenius M. Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J Clin Immunol 2008, 28:220-231. 10.1007/s10875-007-9157-0, 18071879.
54. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007, 13:543-551. 10.1038/nm1590, 17479100.
55. Miettinen M, Sareneva T, Julkunen I, Matikainen S. IFNs activate toll-like receptor gene expression in viral infections. Genes Immun 2001, 2:349-355. 10.1038/sj.gene.6363791, 11607792.
56. Davis AM, Ramos HJ, Davis LS, Farrar JD. Cutting edge: a T-bet-independent role for IFN-α/β in regulating IL-2 secretion in human CD4+ central memory T cells. J Immunol 2008, 181:8204-8208. 2596627, 19050236.
57. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19:225-234. 10.1016/S1074-7613(03)00208-5, 12932356.
58. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, Tough DF. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 2006, 176:2074-2078.
59. Uccellini MB, Busconi L, Green NM, Busto P, Christensen SR, Shlomchik MJ, Marshak-Rothstein A, Viglianti GA. Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-α. J Immunol 2008, 181:5875-5884. 2584609, 18941176.
60. Båve U, Vallin H, Alm GV, Rönnblom L. Activation of natural interferon-α producing cells by apoptotic U 937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun 2001, 17:71-80. 10.1006/jaut.2001.0519, 11488639.
61. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005, 102:3372-3377. 552921, 15728381, 10.1073/pnas.0408506102.
62. Eloranta ML, Lovgren T, Finke D, Mathsson L, Ronnelid J, Kastner B, Alm GV, Ronnblom L. Regulation of the interferon-α production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum 2009, 60:2418-2427. 10.1002/art.24686, 19644885.
63. Lee HM, Mima T, Sugino H, Aoki C, Adachi Y, Yoshio-Hoshino N, Matsubara K, Nishimoto N. Interactions among type I and type II interferon, tumor necrosis factor, and beta-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus. Arthritis Res Ther 2009, 11:R1. 2688231, 19121222, 10.1186/ar2584.
64. Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. Interferon-α in lupus psychosis. Arthritis Rheum 1992, 35:417-422. 10.1002/art.1780350410, 1373622.
65. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005, 19:105-123. 1255968, 15697325, 10.2165/00023210-200519020-00002.
66. Santer DM, Yoshio T, Minota S, Moller T, Elkon KB. Potent induction of IFN-α and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol 2009, 182:1192-1201. 2745922, 19124763.
67. Fairhurst AM, Mathian A, Connolly JE, Wang A, Gray HF, George TA, Boudreaux CD, Zhou XJ, Li QZ, Koutouzov S, Banchereau J, Wakeland EK. Systemic IFN-α drives kidney nephritis in B6.Sle123 mice. Eur J Immunol 2008, 38:1948-1960. 2699327, 18506882, 10.1002/eji.200837925.
68. Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, McCune WJ, Kaplan MJ. Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007, 110:2907-2915. 2018671, 17638846, 10.1182/blood-2007-05-089086.
69. Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM. Synergistic proinflammatory effects of the antiviral cytokine interferon-α and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation 2007, 116:2043-2052. 10.1161/CIRCULATIONAHA.107.697789, 17938289.
70. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005, 52:1491-1503. 10.1002/art.21031, 15880830.
71. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54:2951-2962. 10.1002/art.22044, 16947629.
72. Landolt-Marticorena C, Bonventi G, Lubovich A, Ferguson C, Unnitahn T, Su J, Gladman DD, Urowitz M, Fortin PR, Wither J. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009, 68:1440-1446. 10.1136/ard.2008.093146, 18772188.
73. Petri M, Singh S, Tesfasyone H, Dedrick R, Fry K, Lal P, Williams G, Bauer J, Gregersen P, Behrens T, Baechler E. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009, 18:980-989. 10.1177/0961203309105529, 19762399.
74. Baechler EC, Batliwalla FM, Ortmann WA, Espe KJ, Hughes KM, Wenberg NH, Kern M, Novitzke JM, Slattery CA, Koeuth T, Bauer JW, Tesfoyne H, Singh S, Petri M, Gregersen PK, Behrens TW. Gene signatures in peripheral blood predict future disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52:S700.
75. Petri M, Tesfasyone H, Singh S, Batliwalla F, Gregersen PK, Gillespie E, Ortmann WA, Espe KJ, Hughes KM, Wenberg NH, Slattery CA, Koeuth T, Behrens T. The systemic lupus erythematosus interferon signature is associated with current activity and is also predictive of hematologic and mucocutaneous disease activity at the next visit. Arthritis Rheum 2005, 52:S464.
76. Biesen R, Demir C, Barkhudarova F, Grun JR, Steinbrich-Zollner M, Backhaus M, Haupl T, Rudwaleit M, Riemekasten G, Radbruch A, Hiepe F, Burmester GR, Grutzkau A. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 2008, 58:1136-1145. 10.1002/art.23404, 18383365.
77. Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, Espe KJ, Li W, Patel DD, Gregersen PK, Behrens TW. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006, 3:e491. 1702557, 17177599, 10.1371/journal.pmed.0030491.
78. Fu Q, Chen X, Cui H, Guo Y, Chen J, Shen N, Bao C. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Ther 2008, 10:R112. 2592795, 18793417, 10.1186/ar2510.
79. Svenungsson E, Gustafsson J, Leonard D, Sandling J, Gunnarsson I, Nordmark G, Jönsen A, Bengtsson AA, Sturfelt G, Rantapää-Dahlqvist S, Elvin K, Sundin U, Garnier S, Simard JF, Sigurdsson S, Padyukov L, Syvänen AC, Rönnblom L. A STAT4 risk allele is associated with ischemic cerebrovascular events and antiphospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2009,
80. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, Theofilopoulos AN. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003, 197:777-788. 2193854, 12642605, 10.1084/jem.20021996.
81. Braun D, Geraldes P, Demengeot J. Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003, 20:15-25. 10.1016/S0896-8411(02)00109-9, 12604309.
82. Wallac DJ, Petri M, Olsen N, Kirou K, Dennis G, Yao Y, Jallal B, Coyle A, Zeng L, Investigators L, White B. MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinicla activity in systemic lupus erythematosus. Arthritis Rheum 2007, 56:S562-S563.
83. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B. Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-a monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009, 60:1785-1796. 10.1002/art.24557, 19479852.
84. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004, 202:8-32. 10.1111/j.0105-2896.2004.00204.x, 15546383.
85. Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, Gunther G, Johnston I, Lanzavecchia A, Nagasaka T, Okada T, Vermi W, Winkels G, Yamamoto T, Zysk M, Yamaguchi Y, Schmitz J. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. J Exp Med 2001, 194:1823-1834. 2193584, 11748283, 10.1084/jem.194.12.1823.
86. Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 2008, 223:271-283. 10.1111/j.1600-065X.2008.00630.x, 18613842.
87. Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008, 17:394-399. 10.1177/0961203308090020, 18490415.